NCT06569680View on ClinicalTrials.gov

Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 19, 2024

Primary Completion Date

December 1, 2030

Study Completion Date

December 1, 2030

Conditions
Extranodal Marginal Zone Lymphoma
Interventions
DRUG

Mosunetuzumab

"Mosunetuzumab will be administered via subcutaneous (SC) injection using a step-up dosing model. Participants will receive Mosunetuzumab on days 1, 8, and 15 of Cycle 1, and on day 1 of Cycles 2 through 8 as follows:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 45mg~* Cycle 1 Day 15: 45mg~* Cycles 2 through 8, Day 1: 45mg"

Trial Locations (1)

33136

RECRUITING

University of Miami, Miami

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Izidore Lossos, MD

OTHER